Atossa Therapeutics, Inc. advances Z-endoxifen pipeline with key U.S. FDA designations into 2026

Traders Union
All News
Companies
Atossa accelerates Z-endoxifen pipeline

Top Stories

Editors' Picks

Crypto News

Financial News

Currencies

Market Voices

Billionaires

Companies

Regulators News

Olesia Kramarenko

09.04.2026

Atossa Therapeutics, Inc. advances Z-endoxifen pipeline with key U.S. FDA designations into 2026 — Atossa accelerates Z-endoxifen pipeline

Atossa Therapeutics, Inc. is accelerating progress into 2026 with its Z-endoxifen clinical program in oncology and rare diseases.

The company announced that it has secured important U.S. FDA designations and brought in new clinical leadership, underscoring its commitment to scientific rigor and future milestones. Atossa Therapeutics, Inc. aims to strengthen its development pipeline and deliver on strategic goals as it leverages growing scientific validation across its core therapeutic areas.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Atossa Therapeutics previously revealed new breast cancer research at the NCCN Annual Conference with a detailed scientific poster. The company also shared findings from its (Z)-endoxifen clinical trial at the MDA Clinical and Scientific Conference. These presentations reflect ongoing activity in both breast cancer and endoxifen-related studies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Five years with Bitcoin: How El Salvador changed after legalizing BTC

By Eugene Komchuk
12 hours ago

Five years with Bitcoin: How El Salvador changed after legalizing BTC

Editors' Picks

Crypto on the court: How NBA Finals became a showcase for Ledger

By Anastasiia Chabaniuk
Yesterday

Crypto on the court: How NBA Finals became a showcase for Ledger

Editors' Picks

How to build wealth from scratch in 3 practical steps

By Johnathan Maverick
08.06.2026

How to build wealth from scratch in 3 practical steps

Editors' Picks

All Editors' Top Picks

Latest Atossa News

Lowering mammographic breast density could cut future cancer risk, ATOSSA THERAPEUTICS, INC. asserts

By Elena Nikulina
08.06.2026

Lowering mammographic breast density could cut future cancer risk, ATOSSA THERAPEUTICS, INC. asserts

Companies

Atossa Therapeutics unveils findings on complexity of Duchenne muscular dystrophy beyond protein loss

By Igor Krasulya
04.06.2026

Atossa Therapeutics unveils findings on complexity of Duchenne muscular dystrophy beyond protein loss

Companies

Atossa Therapeutics convenes leading experts for Endoxifen therapy virtual session

By Ivan Andriyenko
22.05.2026

Atossa Therapeutics convenes leading experts for Endoxifen therapy virtual session

Companies

All Atossa News

Eugene Komchuk
12 hours ago

Five years with Bitcoin: How El Salvador changed after legalizing BTC

Anastasiia Chabaniuk
Yesterday

Crypto on the court: How NBA Finals became a showcase for Ledger

Johnathan Maverick
08.06.2026

How to build wealth from scratch in 3 practical steps

Eugene Komchuk
08.06.2026

Kospi Index crash: Why South Korean market fell alongside AI stocks

Mira Kyivska
07.06.2026

Bitcoin or Ferrari: Which investment is better?

Jose Antonio Gastelum
9 min ago

Brian Armstrong: Coinbase approved to offer global crypto perpetuals in U.S.

Ivan Andriyenko
9 min ago

Coca-Cola holds at peak while crypto and tech slide, Charlie Bilello notes

Mikhail Vnuchkov
14 min ago

Proshares sought Lehman approval for leveraged ETFs in 2004, Jared Dillian notes

Yulia Slavina
24 min ago

Keith McCullough: Long Only portfolio declined 11 bps amid aggressive Quad Shift

Hlib Chabaniuk
24 min ago

Gabor Gurbacs: Domino’s Pizza no longer top performing long term investment

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Olga Shendetskaya
6 hours ago

Hot CPI report puts new pressure on U.S. stocks

Hot CPI report puts new pressure on U.S. stocks

Igor Krasulya
7 hours ago

Kalshi adds XRP to regulated perpetual futures market

Kalshi adds XRP to regulated perpetual futures market

Olga Shendetskaya
8 hours ago

Global bond sales climb as defense spending and refinancing needs grow

Global bond sales climb as defense spending and refinancing needs grow

Hanna Syniavska
10 hours ago

SoftBank shares fall 8% as OpenAI-backed loan talks stall

SoftBank shares fall 8% as OpenAI-backed loan talks stall

Andrey Mastykin
11 hours ago

CLARITY Act talks hit new obstacles in Senate

CLARITY Act talks hit new obstacles in Senate

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Alphabet remains under pressure as AI drives growth outlook

Mykhailo Ihnatenko
Now

Tesla tests investor confidence amid tech sector sell-off

Anton Kharitonov
Now

Microsoft tests major support as pressure on shares persists after record expectations

Mykhailo Ihnatenko
Now

AMD retreats as AI rally cools and investors take profits

Anton Kharitonov
Now

Apple continues to decline as capex weighs on the stock

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.